Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Palo Alto, CA, May 15, 2026 (GLOBE NEWSWIRE) -- In recognition of World Hypertension Day 2026, Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., joins the...
-
UroGen Announces 36 mo DOR from the UTOPIA trial studying UGN-103 for the treatment of LG-IR-NMIBC
-
Global Viral Inactivation Market to reach USD 2.27 billion by 2035, driven by rising biologics production and demand for viral safety solutions.
-
Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "South Africa IVD Centralized Diagnostics Market (By Segment - Immunoassay, Clinical Chemistry, Coagulation, Hematology, Urinalysis, Rest of Centralized...
-
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s...
-
Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Vasculan Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report delivers detailed insights...
-
Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "OXBRYTA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The OXBRYTA sales forecast report...
-
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy...
-
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer...
-
Expanded dosing options support individualized treatment for adults with XLH PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd.,...